[{"id":"37515089-1ee4-4286-99b0-7bb0298fc653","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472153","created_at":"2026-03-28T01:41:57.745Z","updated_at":"2026-03-28T01:41:57.745Z","phase":"Phase 2/3","brief_title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","source_id_and_acronym":"NCT07472153","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"a334d333-a3ba-49e5-a0c5-4e85464ed3d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470489","created_at":"2026-03-28T01:44:21.005Z","updated_at":"2026-03-28T01:44:21.005Z","phase":"Phase 2","brief_title":"A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial","source_id_and_acronym":"NCT07470489","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/30/2026","start_date":" 09/30/2026","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2026-03-13"},{"id":"18a3da62-b5a9-4d54-8e87-dde3f9c60f1b","acronym":"HARMONI","url":"https://clinicaltrials.gov/study/NCT07211139","created_at":"2025-10-11T01:28:12.030Z","updated_at":"2025-10-11T01:28:12.030Z","phase":"","brief_title":"Head and Neck Advanced Research for Multi-Omics and Optimized Immunotherapy","source_id_and_acronym":"NCT07211139 - HARMONI","lead_sponsor":"Samsung Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/08/2025","start_date":" 07/08/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-10-07"},{"id":"d56691d6-631f-4daa-9d9c-1b3527ec47af","acronym":"SAFE ESO","url":"https://clinicaltrials.gov/study/NCT07205731","created_at":"2025-10-11T01:29:40.189Z","updated_at":"2025-10-11T01:29:40.189Z","phase":"Phase 2","brief_title":"Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","source_id_and_acronym":"NCT07205731 - SAFE ESO","lead_sponsor":"University Hospital, Clermont-Ferrand","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2025-10-03"},{"id":"87abc85a-8507-4bc1-aa8b-b9b9b0d2d2c7","acronym":"HOPE","url":"https://clinicaltrials.gov/study/NCT07190573","created_at":"2025-09-27T08:41:15.516Z","updated_at":"2025-09-27T08:41:15.516Z","phase":"","brief_title":"Head and Neck Cancer Omics/Integrated Precision Medicine (HOPE)","source_id_and_acronym":"NCT07190573 - HOPE","lead_sponsor":"Samsung Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 04/25/2025","start_date":" 04/25/2025","primary_txt":" Primary completion: 01/31/2030","primary_completion_date":" 01/31/2030","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-09-24"},{"id":"ab44ad05-9bd9-4db7-9ebb-ab1b8496e06f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190027","created_at":"2025-09-27T08:39:53.097Z","updated_at":"2025-09-27T08:39:53.097Z","phase":"Phase 1/2","brief_title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","source_id_and_acronym":"NCT07190027","lead_sponsor":"First Affiliated Hospital of Wenzhou Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 246","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-09-24"},{"id":"b11c3dd5-a7d2-45b9-88bd-188586703589","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190248","created_at":"2025-09-27T08:39:58.068Z","updated_at":"2025-09-27T08:39:58.068Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","source_id_and_acronym":"NCT07190248","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":"","alterations":" ","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 10/27/2025","start_date":" 10/27/2025","primary_txt":" Primary completion: 12/07/2029","primary_completion_date":" 12/07/2029","study_txt":" Completion: 08/06/2032","study_completion_date":" 08/06/2032","last_update_posted":"2025-09-24"},{"id":"e3849c3a-6be4-415c-bb15-50c8c05581ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190833","created_at":"2025-09-27T08:40:11.891Z","updated_at":"2025-09-27T08:40:11.891Z","phase":"Phase 1","brief_title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)","source_id_and_acronym":"NCT07190833","lead_sponsor":"Bionoxx Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • hydroxyurea"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-09-24"},{"id":"87b594ce-090b-4f4f-8607-c4cad1156d5d","acronym":"SAH","url":"https://clinicaltrials.gov/study/NCT07180966","created_at":"2025-09-20T07:04:29.480Z","updated_at":"2025-09-20T07:04:29.480Z","phase":"","brief_title":"Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation","source_id_and_acronym":"NCT07180966 - SAH","lead_sponsor":"Ruijin Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 780","initiation":"Initiation: 09/12/2025","start_date":" 09/12/2025","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-09-18"},{"id":"b3d11c4b-a1ab-423b-985e-6d16fd2ac00a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07179757","created_at":"2025-09-20T07:05:19.549Z","updated_at":"2025-09-20T07:05:19.549Z","phase":"","brief_title":"Clinical Outcomes and Quality of Life in Patients With Locally Advanced Vulvovaginal Cancers: Ambispective Registration Study.","source_id_and_acronym":"NCT07179757","lead_sponsor":"Tata Memorial Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/30/2021","start_date":" 10/30/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-09-18"},{"id":"744cefa6-7afb-4f15-a0be-a9b48479230c","acronym":"SURGAN-ICI","url":"https://clinicaltrials.gov/study/NCT07177105","created_at":"2025-09-20T07:06:49.764Z","updated_at":"2025-09-20T07:06:49.764Z","phase":"Phase 2","brief_title":"Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC","source_id_and_acronym":"NCT07177105 - SURGAN-ICI","lead_sponsor":"Jianxing He","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Tyvyt (sintilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2025-09-16"},{"id":"a3f2cdb8-5f51-4d49-bdd8-408b76b63c70","acronym":"ZANGEA","url":"https://clinicaltrials.gov/study/NCT07176312","created_at":"2025-09-20T07:08:39.876Z","updated_at":"2025-09-20T07:08:39.876Z","phase":"Phase 2","brief_title":"Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","source_id_and_acronym":"NCT07176312 - ZANGEA","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-09-16"},{"id":"d70dbe69-fc0c-4491-b69e-8481a8fc0c63","acronym":"","url":"https://clinicaltrials.gov/study/NCT07170592","created_at":"2025-09-20T07:09:01.411Z","updated_at":"2025-09-20T07:09:01.411Z","phase":"Phase 1","brief_title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients","source_id_and_acronym":"NCT07170592","lead_sponsor":"Bionoxx Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • hydroxyurea"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-09-12"},{"id":"9878563c-8961-4069-b799-4ed976e57f17","acronym":"RICEPS-2","url":"https://clinicaltrials.gov/study/NCT07163507","created_at":"2025-09-13T08:43:08.345Z","updated_at":"2025-09-13T08:43:08.345Z","phase":"","brief_title":"Immune Response Under Immunotherapy in Lung Cancer: Study of Sputum Samples","source_id_and_acronym":"NCT07163507 - RICEPS-2","lead_sponsor":"University Hospital, Tours","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-09-09"},{"id":"8429aef2-3578-430a-8f3c-fc5f753d6982","acronym":"","url":"https://clinicaltrials.gov/study/NCT07161453","created_at":"2025-09-13T08:46:03.641Z","updated_at":"2025-09-13T08:46:03.641Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","source_id_and_acronym":"NCT07161453","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-09-08"},{"id":"a6d31c69-7c36-43a0-bc25-c25fb37e0176","acronym":"AGA TKI NSCLC","url":"https://clinicaltrials.gov/study/NCT07158840","created_at":"2025-09-13T08:44:13.914Z","updated_at":"2025-09-13T08:44:13.914Z","phase":"Phase 2","brief_title":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment","source_id_and_acronym":"NCT07158840 - AGA TKI NSCLC","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/05/2025","start_date":" 09/05/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-09-08"},{"id":"fae12559-05ff-4175-9322-233f03620f30","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159828","created_at":"2025-09-13T08:45:52.032Z","updated_at":"2025-09-13T08:45:52.032Z","phase":"Phase 1","brief_title":"A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07159828","lead_sponsor":"Instil Bio","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2025-09-08"},{"id":"27751dcd-f28f-4f36-b8db-e4042ae9fc77","acronym":"CVL006-T1002","url":"https://clinicaltrials.gov/study/NCT07157956","created_at":"2025-09-13T08:47:52.158Z","updated_at":"2025-09-13T08:47:52.158Z","phase":"Phase 1/2","brief_title":"CVL006 Combination Therapy in Advanced Solid Tumors","source_id_and_acronym":"NCT07157956 - CVL006-T1002","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 08/12/2028","primary_completion_date":" 08/12/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-09-05"},{"id":"f548789f-e984-493e-8c25-7196761bc8df","acronym":"","url":"https://clinicaltrials.gov/study/NCT07153952","created_at":"2025-09-06T13:40:49.515Z","updated_at":"2025-09-06T13:40:49.515Z","phase":"Phase 1/2","brief_title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","source_id_and_acronym":"NCT07153952","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-09-04"},{"id":"716dc364-32b8-4cd4-ad8c-813b9359535b","acronym":"PB-PD1R-SCC","url":"https://clinicaltrials.gov/study/NCT07147361","created_at":"2025-09-07T01:05:27.471Z","updated_at":"2025-09-07T01:05:27.471Z","phase":"","brief_title":"Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma","source_id_and_acronym":"NCT07147361 - PB-PD1R-SCC","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-08-29"},{"id":"efd9f946-f015-462e-a89d-d7d3988373c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07149181","created_at":"2025-08-30T13:47:49.395Z","updated_at":"2025-08-30T13:47:49.395Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery","source_id_and_acronym":"NCT07149181","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 08/31/2025","start_date":" 08/31/2025","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-08-29"},{"id":"37fa384b-e7a2-4ce7-847c-4eaff8ded1d9","acronym":"SPRINT 2","url":"https://clinicaltrials.gov/study/NCT07146230","created_at":"2025-08-30T13:48:56.537Z","updated_at":"2025-08-30T13:48:56.537Z","phase":"Phase 2","brief_title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","source_id_and_acronym":"NCT07146230 - SPRINT 2","lead_sponsor":"Montefiore Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-08-28"},{"id":"f4e7bfa0-b752-484d-96c0-7b0fd411e68b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07144280","created_at":"2025-08-30T13:50:25.910Z","updated_at":"2025-08-30T13:50:25.910Z","phase":"Phase 3","brief_title":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT07144280","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • PF-08046054"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 08/22/2025","start_date":" 08/22/2025","primary_txt":" Primary completion: 03/10/2028","primary_completion_date":" 03/10/2028","study_txt":" Completion: 03/10/2032","study_completion_date":" 03/10/2032","last_update_posted":"2025-08-27"},{"id":"ec6be1b2-4bb2-4f7d-914f-ec7b055df2df","acronym":"DECIDING","url":"https://clinicaltrials.gov/study/NCT07142200","created_at":"2025-08-30T13:52:10.410Z","updated_at":"2025-08-30T13:52:10.410Z","phase":"Phase 2","brief_title":"A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection","source_id_and_acronym":"NCT07142200 - DECIDING","lead_sponsor":"RenJi Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-08-26"}]